Net Loss per Share

6 Months Ended

Jun. 30, 2024

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except share and per share amounts)	2024		2023		2024		2023
Numerator:



Net loss attributable to common stockholders	$	(55,327)	$	(42,385)	$	(101,088)	$	(81,782)
Denominator:
Weighted-average common shares outstanding, basic and diluted	119,188,866		90,467,298		111,827,522		89,769,970
Net loss per share attributable to common stockholders, basic and diluted	$	(0.46)	$	(0.47)	$	(0.90)	$	(0.91)

The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants sold by the Company to purchase 3,200,005 shares of the Company's common stock. The shares of common stock underlying the pre-funded warrants are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested, and the pre-funded warrants are immediately exercisable upon their issuance date.

Diluted net loss per share available to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock and stock options to purchase common stock were considered common stock equivalents but had been excluded from the calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of June 30,
	2024	2023
Anti-dilutive common stock equivalents:
Options to purchase common stock	12,007,443	7,325,808
Unvested restricted common stock	3,729,877	6,140,806
Total anti-dilutive common stock equivalents:	15,737,320	13,466,614